.

Legal Updates for Asbestos and Mass Tort Litigation

New Jersey Appellate Division Strikes Down $117M Verdict in Talc/Asbestos Case Because Trial Court Did Not Properly Assess Plaintiffs’ Expert Opinions

Legal Updates for Asbestos & Mass Tort Litigation – April 30, 2021

April 30, 2021

by Paul C. Johnson

In April 2018, a Middlesex County jury returned a verdict against Johnson & Johnson Consumer, Inc. and Imerys Talc America, Inc., finding that the plaintiff, Stephen Lanzo, was exposed to asbestos from Johnson’s baby powder and Shower to Shower powder and that this exposure caused his mesothelioma. The jury awarded $30 million in compensatory damages to Stephen Lanzo, $7 million to Kendra Lanzo for loss of consortium, and subsequently entered punitive damages awards of $55 million against Johnson & Johnson and $25 million against Imerys, for a total verdict of $117 million.

Both defendants appealed, arguing that the trial judge erred by admitting unreliable expert testimony. Johnson & Johnson also appealed the trial court’s denial of their motion to sever the plaintiffs’ claims against them from the claims against Imerys based on an adverse inference jury charge against Imerys. The Appellate Division agreed with the defendants, reversing the trial court judgment and remanding the matter to the Law Division for a new trial. On the adverse inference issue, the Appellate Division held that the new trials should be conducted separately in order to avoid any potential prejudice to Johnson & Johnson caused by the adverse inference charge against Imerys.

Expert – Gatekeeper Role

Both defendants challenged the expert opinions expressed by two of the plaintiffs’ expert witnesses, Dr. Jacqueline Moline and Dr. James Webber, that non-asbestiform cleavage fragments from certain minerals could cause mesothelioma. The trial judge denied the defendants’ request for a Rule 104 hearing. The defendants contended that by permitting these experts to testify, the trial judge misapplied the well-established gatekeeping procedures required to be handled by the trial court and as required by In re Accutane Litigation (Accutane), 234 N.J. 340, 388 (2018). The Appellate Division noted that the Supreme Court decision in Accutane essentially reconciled New Jersey Rules of Evidence with the longstanding Federal evidence standard expressed in Daubert v. Merrell Dow Pharms., Inc., 509 U.S. 579 (1993).

An expert’s opinion on causation may be admitted when it is “based on sound, adequately founded scientific methodology involving data and information of the type reasonably relied on by experts in the scientific field.” Accutane, at 349-350. The trial court is required to assess the soundness of the preferred methodology and the underlying data used to formulate the opinion in evaluating the qualifications of the expert and the conclusions. When a proponent fails to demonstrate “the soundness of a methodology, both in terms of its approach to reasoning and to its use of data, from the perspective of others within the relevant scientific community, the gatekeeper should exclude the proposed expert testimony on the basis that it is unreliable.” Lanzo v. Johnson & Johnson, (slip op. p. 34-35).

Here, both Drs. Moline and Webber testified that non-asbestiform cleavage fragments can cause mesothelioma. The trial judge only noted that “the issue of cleavage fragments was an area that’s highly contested between plaintiff’s experts and defense experts,” but the judge did not evaluate the issues in context. Lanzo, (slip op. p. 41). The trial judge also denied the defendants’ motion for a Rule 104 hearing on the experts’ opinions on this issue.

The Appellate Division found that the trial court did not assess the methodology or the underlying data used by these experts, noting that Dr. Webber had not conducted any studies and was not aware of any studies showing that non-asbestiform cleavage fragments could cause mesothelioma. Dr. Moline had previously testified that non-asbestiform cleavage fragments could not cause mesothelioma. At trial in this case, she testified that she had changed her opinion on this issue over time. However, she did not express any scientific basis for the change in her opinion.

The Appellate Division determined that the trial judge did not perform the required gatekeeping function by failing to evaluate the methodology or the data and information that formed the basis for the expert conclusions put forth by Drs. Webber and Moline. The Appellate Division also determined that those errors were clearly capable of producing an unjust result, which required a new trial.

Adverse Inference

In their discovery responses, Imerys certified that it did not have and was not aware of any historical talc samples or testing documents. At trial, however, Imerys’ representative confirmed that Imerys had, at one time, been in possession of historical talc samples and testing documents, but they had discarded the talc samples and documents.

The trial court determined that discarding these items was not intentional, however, recognized that spoliation does not require intent. The court noted that the purpose of an adverse inference charge is to level the playing field where evidence has been hidden or destroyed. To accomplish this levelling, the trial court included a jury charge that stated, “You may infer that the missing evidence may have been helpful to the plaintiffs’ case to the detriment of defendant Imerys.” The trial court also specifically charged that Johnson & Johnson was not involved in the spoliation conduct and that the adverse inference should not be drawn as to any other defendant in the case.

The Appellate Division noted that New Jersey court rules permit separate trials in order to prevent prejudice. R. 4:29-2 & R. 4:38-2(a). Severance may be appropriate “where a significant portion of the evidence to be adduced at trial is admissible only as to one defendant thereby causing prejudice to other defendants.” State v. Mance, 300 N.J. Super. 37, 53 (App. Div. 1997).

The Appellate Division found that, once the jury was permitted to draw an adverse inference that Imerys’ talc was contaminated with asbestos, it would likely be impossible for the jury to make a different finding as to Johnson & Johnson. The Appellate Division held that the trial court erred in failing to sever the claims against Imerys from the claims against Johnson & Johnson and remanded the matter to the trial court for separate trials against each defendant.

 

 

Legal Updates for Asbestos & Mass Tort Litigation – April 30, 2021, has been prepared for our readers by Marshall Dennehey Warner Coleman & Goggin. It is solely intended to provide information on recent legal developments, and is not intended to provide legal advice for a specific situation or to create an attorney-client relationship. We welcome the opportunity to provide such legal assistance as you require on this and other subjects. If you receive the alerts in error, please send a note to tdrau@mdwcg.com. ATTORNEY ADVERTISING pursuant to New York RPC 7.1. © 2021 Marshall Dennehey Warner Coleman & Goggin. All Rights Reserved.

Firm Highlights

Thought Leadership

Congress Passes Financial Exploitation Prevention Act

On June 25, 2026, the House passed the Financial Exploitation Prevention Act of 2025 (“the Act”) by a vote of 414 to 2. The Act allows financial advisors and firms to delay suspicious transactions regarding the accounts of clients who are 65 or older, if they believe financial exploitation has occurred or is about to take place. With the advancement of technology and AI, the House’s overwhelming bipartisan passage of the Financial Exploitation Prevention Act represents an important step in strengthening the financial industry’s ability to combat the growing threat of elder financial exploitation. The Act recognizes what advisors have long known that financial professionals are often the first to detect suspicious behavior but have historically lacked clear legal authority to intervene before irreversible financial harm occurs. From the industry’s perspective, the bill accomplishes several important objectives, including the following: (1) Provides a practical “pause button” by allowing financial professionals to temporarily delay certain transaction requests when there is a reasonable belief that a senior or vulnerable adult is being financially exploited; (2) Empowers financial professionals to act by providing greater certainty that firms can act in good faith to protect clients without unnecessary legal risk; and (3) Strengthens investor protection without sacrificing client rights by allowing temporary delays based on a reasonable suspicion of exploitation, which is intended only to allow additional review and not to deny clients access to their money indefinitely. In sum, the Financial Exploitation Prevention Act will equip financial professionals with practical, carefully tailored tools to stop suspected financial exploitation before client assets are lost. By allowing firms to temporarily delay suspicious transactions under defined circumstances, Congress is recognizing the critical role advisors play as the first line of defense against increasingly sophisticated fraud schemes. The Act strikes an appropriate balance between protecting vulnerable investors and preserving individual financial autonomy, while reinforcing collaboration among advisors, families, and law enforcement to combat financial exploitation. The bill now awaits Senate action.

Result

No-Cause Jury Verdict Secured in Wrongful Death Trial

We successfully obtained a no-cause jury verdict in a 13-day wrongful death trial. The decedent, a 59-year-old man, was admitted to the emergency room on February 15, 2019, with complaints of abdominal pain, decreased appetite, and constipation, despite the use of laxatives. The patient did not complain of any nausea, vomiting, or diarrhea. He had a significant medical history including diabetes, hypertension, prior coronary artery stenting, morbid obesity (with past gastric bypass surgery), longstanding ventral hernia, and back pain. A CT scan revealed multiple hernias and a potential closed-loop bowel obstruction, leading to a surgery consultation. Our client, an emergency general surgeon, interpreted that the patient did not have a closed loop or any significant obstruction and recommended non-surgical management. The patient was approved to have clear liquids, and had a vomiting incident shortly after, but our client was not notified. The patient was returned to NPO status, and after improving overnight, he was returned to “clears” and additional medical and renal consults were ordered. Our client did not receive any communications from the residents/nurses of any changes in the patient’s condition. On February 18, 2019, two rapid responses were called due to increased heart rate and vomiting. It is believed that the vomiting resulted in aspiration, causing sepsis, ultimately leading to the patient’s death. During the trial, the plaintiff’s sole medical expert highlighted imaging on the wrong hernia, which called into question all of his opinions in the case. We made key objections related to the expert testimony, limiting what the allegations were, and preventing new allegations from being made. After approximately two and a half hours of deliberating, the jury returned a no-cause verdict. 

Thought Leadership

New Jersey Expands Family Leave Protections Effective July 17, 2026

On January 17, 2026, Governor Murphy signed into law legislation expanding the New Jersey Family Leave Act (NJFLA). Beginning July 17, 2026, significant amendments to the NJFLA will expand job-protected family leave to smaller businesses and more employees across the state. The new law broadens coverage by lowering the threshold for private employers from 30 employees to 15 employees, meaning many smaller businesses will now be subject to the NJFLA. Employees of state and local government agencies will continue to be covered regardless of the size of the employer. The amendments also make it easier for employees to qualify for leave. Under the revised law, an employee will be eligible after three months of employment and at least 250 hours worked during the preceding 12 months, replacing the previous requirement of 12 months of employment and 1,000 hours worked. Currently, New Jersey's Temporary Disability Insurance (TDI) and Family Leave Insurance (FLI) programs provide eligible employees with wage replacement while they are on leave but do not independently guarantee job protection. The recent amendments to the New Jersey Family Leave Act (NJFLA) expand these protections by extending job-protected leave to additional employees. Under the amended law, employees receiving TDI or FLI benefits may be entitled to return to the same position they held before taking leave, or to an equivalent position with the same seniority, status, pay, and benefits. Although the legislation also states that it does not expand or modify an employee's reinstatement rights under the NJFLA, the amendments appear to provide job protection to eligible employees receiving TDI or FLI benefits without requiring them to separately satisfy the eligibility requirements of the NJFLA or the federal Family and Medical Leave Act (FMLA). As a result, some employees may be entitled to longer periods of job-protected leave than were previously available under existing law. With these amendments, New Jersey continues to strengthen workplace protections by expanding access to job-protected family leave for eligible employees. These changes significantly expand access to job-protected family leave and may require employers to update their leave policies, employee handbooks, and HR practices. Notably, employers who were previously not required to administer NJFLA may need to amend their policies and/or create new protocols to come into compliance with the NJFLA. Failure to do so would prove costly, as the penalties for non-compliance are significant.

Thought Leadership

Mitigating Long-Tail Liability: Delaware Court Reaffirms Five-Year Workers’ Compensation Deadline

Williamson v. Donald F. Deaven, Inc., No. N25A-07-004 FWW, 2026 LX 252526 (Del. Super. Ct. June 2, 2026) Claimant was involved in a compensable industrial work accident on May 12, 1995, for a low back injury.  Following this, he received compensation for temporary total disability benefits from July 1996 to September 1996 and for sustaining a permanent impairment in 1997 and 1998. For the next 23 years, the claimant continued treatment and paid his own medical bills without submitting them to the employer’s insurer. In November 2021, the claimant filed a petition seeking payment for medical expenses, including prospective surgery and a resulting period of total disability. The employer moved to dismiss the petition, arguing it was barred by Delaware’s five-year statute of limitations (19 Del. C. § 2361(b)). Pursuant to 18 Del. C. § 3914, insurers must provide prompt written notice of the applicable statute of limitations to invoke the five-year deadline. Due to the age of the case, neither party had a comprehensive file of the claim and the Board had archived its file of the matter. The carrier’s computer system retained only bare information indicating that payments occurred and agreements and receipts were filed with the Board in 1997. While the claimant argued that the employer could not prove it provided the mandatory statutory notice, the Hearing Officer recovered the archived file, which contained two “Receipts for Compensation Paid” signed by the claimant. The receipts explicitly contained the required five-year limitation language, which the claimant testified to signing at the hearing. The claimant also attempted to introduce evidence of payments he claimed the employer made, which would have extended the statute of limitations. As a preliminary matter, the hearing officer excluded the testimony about the payments because the claimant did not produce them to the employer. The Board found in favor of the employer and dismissed the claimant’s petition as time-barred. The claimant appealed the Board’s decision, arguing that he never received adequate notice of the statute of limitations and that the hearing officer’s evidentiary ruling was an abuse of discretion. The Court held that the archived, signed receipts constituted substantial evidence that the insurer fulfilled its statutory notice requirements. Therefore, the claimant’s petition was time-barred under the statute of limitations provisions of 19 Del. C. § 2361(b). Furthermore, the Court reinforced strict procedural compliance: it rejected the claimant’s attempts to introduce evidence of payment on appeal, ruling the argument was waived for failure to preserve it while the matter was still before the Board. This recent ruling by the Court underscores the importance and necessity of robust data preservation and precise compliance with notice requirements. For risk managers, employers, and insurers, the decision highlights how tight administrative execution protects against catastrophic long-tail liability.